Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3011011rdf:typepubmed:Citationlld:pubmed
pubmed-article:3011011lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:3011011lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:3011011lifeskim:mentionsumls-concept:C0031441lld:lifeskim
pubmed-article:3011011lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:3011011lifeskim:mentionsumls-concept:C0178463lld:lifeskim
pubmed-article:3011011pubmed:issue10lld:pubmed
pubmed-article:3011011pubmed:dateCreated1986-6-18lld:pubmed
pubmed-article:3011011pubmed:abstractTextIn this study, we used phenoxybenzamine to label the alpha 1-adrenergic receptor of a smooth muscle cell line. Our results demonstrate a dose-dependent occupancy of alpha 1-adrenergic receptors by phenoxybenzamine determined by competition for the [3H]prazosin binding site. Following incorporation of [3H]phenoxybenzamine, partially purified membranes were solubilized and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Despite numerous Coomassie blue-stained bands, only three bands, Mr = 80,000 +/- 500, Mr = 33,000 +/- 2,000, and Mr = 21,000 +/- 400 (N = 4), were labeled with [3H]phenoxybenzamine as determined by autofluorography. Incorporation of [3H]phenoxybenzamine into the Mr = 80,000 band, but not the Mr = 33,000 and Mr = 21,000 bands, was affected by adrenergic agonists and antagonists in a manner consistent with an alpha 1-adrenergic interaction. Labeling of the Mr = 33,000 and Mr = 21,000 bands was partially blocked by phenoxybenzamine. We conclude that [3H]phenoxybenzamine can be used as an affinity probe for the alpha 1-adrenergic receptor and that the ligand binding site of the alpha 1-adrenergic receptor resides in a Mr = 80,000 protein.lld:pubmed
pubmed-article:3011011pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:languageenglld:pubmed
pubmed-article:3011011pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:citationSubsetIMlld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3011011pubmed:statusMEDLINElld:pubmed
pubmed-article:3011011pubmed:monthMaylld:pubmed
pubmed-article:3011011pubmed:issn0006-2952lld:pubmed
pubmed-article:3011011pubmed:authorpubmed-author:CornettL ELElld:pubmed
pubmed-article:3011011pubmed:authorpubmed-author:NorrisJ SJSlld:pubmed
pubmed-article:3011011pubmed:issnTypePrintlld:pubmed
pubmed-article:3011011pubmed:day15lld:pubmed
pubmed-article:3011011pubmed:volume35lld:pubmed
pubmed-article:3011011pubmed:ownerNLMlld:pubmed
pubmed-article:3011011pubmed:authorsCompleteYlld:pubmed
pubmed-article:3011011pubmed:pagination1663-9lld:pubmed
pubmed-article:3011011pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:meshHeadingpubmed-meshheading:3011011-...lld:pubmed
pubmed-article:3011011pubmed:year1986lld:pubmed
pubmed-article:3011011pubmed:articleTitleAffinity labeling of the DDT1 MF-2 cell alpha 1-adrenergic receptor with [3H]phenoxybenzamine.lld:pubmed
pubmed-article:3011011pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3011011pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed